EFPIA calls for new dialogue on medicines
A new dialogue between governments and the pharma industry is being called for by Andrew Witty, CEO of GlaxoSmithKline and President of EFPIA, to address access to and affordability of European medicines, as well as Europe?s competitiveness as a base for R&D investment.
A new dialogue between governments and the pharma industry is being called for by Andrew Witty, CEO of GlaxoSmithKline and President of EFPIA, to address access to and affordability of European medicines, as well as Europe’s competitiveness as a base for R&D investment.
“Many countries in Europe are facing significant pressures in healthcare policy, which have been compounded by the financial crisis,” said Witty in a press statement. “We need a new dialogue between industry and governments to address the difficult questions facing us all on access, on affordability and on innovation.”
Speaking at the 2010 EFPIA General Meeting held in London (UK), Witty explained that the industry must be a “genuine partner” to governments and their agencies, which involves delivering medicines and vaccines that “address unmet needs” and offer “demonstrable added value”. However, he also added that a shared understanding of value between industry and governments is critical. As such, he believes there should be a better dialogue prior to and following marketing authorization.
“Let’s start looking at medicines expenditure as an investment,” said Witty. “This will enable governments and industry to set a strategic agenda for health and pharmaceutical innovation. What matters is whether a medicine works, responds to patient needs and, if so, that it is rewarded.”
EFPIA’s Director General, Brian Ager, also stressed the need for closer cooperation. I want EFPIA to play a part in addressing the challenges faced by governments in balancing tight budgets against the need to ensure sustainable patient access to high healthcare and treatments. A key priority is to ensure that cost controls do not impact quality of care or act as a disincentive to innovation.”
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.
